<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

NEWSROOM Press Releases

    Year
    2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

    254 Results

    Biodesix® Announces Additional Data in Phase III Lung Cancer Diagnostic Study

    October 28, 2013

    PROSE confirms VeriStrat can predict differential treatment outcomes in 2nd line advanced NCLSC patients.

    Peer-Reviewed Study Confirms VeriStrat® Test from Biodesix Provides Useful Information for Physicians in Managing Patients with Lung Cancer

    April 2, 2013

    Study demonstrates that physicians are using the company’s VeriStrat test to help guide treatment decisions for patients with NSCLC.

    Biodesix® and Bioyong Announce Agreement for Joint Development and Commercialization of VeriStrat® Test in Greater China

    January 9, 2017

    Biodesix and Bioyong announced a $38M deal for development and commercialization of VeriStrat in China.

    Biodesix’ Heinrich Roder Presents at 2013 Biomarker Summit

    March 18, 2013

    Dr. Roder will discuss the use of Biodesix’ high throughput mass spectrometry technology, Deep MALDI, to generate protein signatures for Oncology questions.

    Biodesix to Present at World CDx

    November 15, 2013

    Paul Beresford, Ph.D., will present at the 2013 World CDx Summit taking place in Boston, November 12-15, 2013; Benefits of proteomics in test discovery.

    Biodesix Receives Certification from NY State

    March 1, 2011

    Biodesix has received the clinical laboratory evaluation program certification from the New York State Department of Health’s Wadsworth Center.

    Biodesix Issued Four Additional U.S. Patents for Blood-based Oncology Tests

    April 12, 2011

    Biodesix announced that the U.S. Patent & Trademark Office has issued four patents for the protection of the company's products and technology.

    Biodesix Closes Series E Financing

    December 3, 2013

    Biodesix announced today that the company closed an $8.3 million Series E preferred equity financing. Existing shareholders provided all of the capital.

    Biodesix and Capital Royalty Close Financing Transaction

    February 12, 2014

    Biodesix has closed a structured debt financing with Capital Royalty Partners L.P. The transaction provides Biodesix®with up to $20 million of capital.

    Biodesix Adds to Series E Financing

    January 13, 2014

    Biodesix increases the size of its recent offering of series E preferred shares in a follow-on sale; Total series E preferred shares of $14.4 million.
    1 2